Biodesix (BDSX) Competitors $1.19 -0.05 (-4.03%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends BDSX vs. PSNL, XGN, RNLX, AGL, INNV, SHCR, AUNA, FLGT, GRAL, and CELCShould you be buying Biodesix stock or one of its competitors? The main competitors of Biodesix include Personalis (PSNL), Exagen (XGN), Renalytix (RNLX), agilon health (AGL), InnovAge (INNV), Sharecare (SHCR), Auna (AUNA), Fulgent Genetics (FLGT), Grail (GRAL), and Celcuity (CELC). These companies are all part of the "healthcare" industry. Biodesix vs. Personalis Exagen Renalytix agilon health InnovAge Sharecare Auna Fulgent Genetics Grail Celcuity Biodesix (NASDAQ:BDSX) and Personalis (NASDAQ:PSNL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, community ranking, dividends, risk, earnings, media sentiment and valuation. Which has more risk and volatility, BDSX or PSNL? Biodesix has a beta of 1.22, suggesting that its stock price is 22% more volatile than the S&P 500. Comparatively, Personalis has a beta of 1.94, suggesting that its stock price is 94% more volatile than the S&P 500. Is BDSX or PSNL more profitable? Biodesix has a net margin of -66.84% compared to Personalis' net margin of -104.52%. Personalis' return on equity of -66.07% beat Biodesix's return on equity.Company Net Margins Return on Equity Return on Assets Biodesix-66.84% -275.79% -43.05% Personalis -104.52%-66.07%-41.34% Does the media favor BDSX or PSNL? In the previous week, Personalis had 6 more articles in the media than Biodesix. MarketBeat recorded 6 mentions for Personalis and 0 mentions for Biodesix. Personalis' average media sentiment score of 0.42 beat Biodesix's score of -1.00 indicating that Personalis is being referred to more favorably in the news media. Company Overall Sentiment Biodesix Negative Personalis Neutral Which has stronger valuation & earnings, BDSX or PSNL? Biodesix has higher earnings, but lower revenue than Personalis. Biodesix is trading at a lower price-to-earnings ratio than Personalis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiodesix$65.56M2.64-$52.15M-$0.39-3.05Personalis$73.48M3.33-$108.30M-$1.68-2.06 Does the MarketBeat Community believe in BDSX or PSNL? Personalis received 86 more outperform votes than Biodesix when rated by MarketBeat users. However, 74.36% of users gave Biodesix an outperform vote while only 66.47% of users gave Personalis an outperform vote. CompanyUnderperformOutperformBiodesixOutperform Votes2974.36% Underperform Votes1025.64% PersonalisOutperform Votes11566.47% Underperform Votes5833.53% Do institutionals & insiders have more ownership in BDSX or PSNL? 21.0% of Biodesix shares are held by institutional investors. Comparatively, 61.9% of Personalis shares are held by institutional investors. 69.2% of Biodesix shares are held by company insiders. Comparatively, 4.1% of Personalis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts rate BDSX or PSNL? Biodesix presently has a consensus price target of $3.06, indicating a potential upside of 157.14%. Personalis has a consensus price target of $6.81, indicating a potential upside of 96.89%. Given Biodesix's higher possible upside, analysts plainly believe Biodesix is more favorable than Personalis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biodesix 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Personalis 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryPersonalis beats Biodesix on 10 of the 17 factors compared between the two stocks. Ad DarwinNew Year, New Opportunity! 2 AI Stocks Under $10 Ready to SoarAs we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! Get Biodesix News Delivered to You Automatically Sign up to receive the latest news and ratings for BDSX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BDSX vs. The Competition Export to ExcelMetricBiodesixMedical laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$173.11M$3.05B$5.05B$8.87BDividend YieldN/A11.09%4.97%4.06%P/E Ratio-3.0511.1797.3414.18Price / Sales2.64208.381,218.4289.42Price / CashN/A376.8533.5132.79Price / Book23.804.905.805.12Net Income-$52.15M-$32.86M$119.07M$225.99M7 Day Performance-15.00%0.56%-1.83%-1.32%1 Month Performance-25.63%-0.22%-3.64%0.60%1 Year Performance-9.85%26.01%31.62%26.23% Biodesix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BDSXBiodesix2.6834 of 5 stars$1.19-4.0%$3.06+157.1%-16.2%$173.11M$65.56M-3.05220Negative NewsHigh Trading VolumePSNLPersonalis4.1972 of 5 stars$3.46-6.2%$6.81+96.9%+156.3%$260.69M$73.48M0.00400XGNExagen4.7894 of 5 stars$4.20+19.0%$7.00+66.7%+169.2%$62.26M$52.55M0.00220Analyst RevisionGap UpHigh Trading VolumeRNLXRenalytixN/A$0.21+5.7%$3.00+1,348.6%-62.3%$17.18M$2.29M-0.53100Gap UpAGLagilon health2.2481 of 5 stars$1.68+5.7%$6.05+260.1%-85.4%$692.19M$5.59B-1.791,117Analyst ForecastINNVInnovAge1.4851 of 5 stars$4.70-1.7%$6.50+38.3%-19.0%$647.48M$763.85M0.002,350Gap UpSHCRSharecareN/A$1.43flat$1.43N/A$531.79M$445.25M-3.673,352AUNAAuna3.8119 of 5 stars$7.04-2.9%$13.40+90.3%N/A$520.40M$1.04B0.0014,958Short Interest ↓News CoverageFLGTFulgent Genetics4.1478 of 5 stars$17.28+1.6%$28.50+64.9%-37.4%$519.98M$289.21M0.001,184Analyst UpgradeGRALGrailN/A$15.09+2.0%N/AN/A$496.95MN/A0.001,360Insider TradeCELCCelcuity2.3237 of 5 stars$12.78+2.5%$29.17+128.2%-2.3%$474.52MN/A-4.9440 Related Companies and Tools Related Companies PSNL Competitors XGN Competitors RNLX Competitors AGL Competitors INNV Competitors SHCR Competitors AUNA Competitors FLGT Competitors GRAL Competitors CELC Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BDSX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biodesix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biodesix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
